Deep learning-based amyloid PET positivity classification model in the Alzheimer's disease continuum by using 2-[18F]FDG PET.

EJNMMI Research
Suhong KimKBASE Research Group

Abstract

Considering the limited accessibility of amyloid position emission tomography (PET) in patients with dementia, we proposed a deep learning (DL)-based amyloid PET positivity classification model from PET images with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (2-[18F]FDG). We used 2-[18F]FDG PET datasets from the Alzheimer's Disease Neuroimaging Initiative and Korean Brain Aging Study for the Early diagnosis and prediction of Alzheimer's disease for model development. Moreover, we used an independent dataset from another hospital. A 2.5-D deep learning architecture was constructed using 291 submodules and three axes images as the input. We conducted the voxel-wise analysis to assess the regions with substantial differences in glucose metabolism between the amyloid PET-positive and PET-negative participants. This facilitated an understanding of the deep model classification. In addition, we compared these regions with the classification probability from the submodules. There were 686 out of 1433 (47.9%) and 50 out of 100 (50%) amyloid PET-positive participants in the training and internal validation datasets and the external validation datasets, respectively. With 50 times iterations of model training and validation, the model achiev...Continue Reading

References

May 1, 1995·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·K J Friston
May 1, 1997·Journal of the Neurological Sciences·A TamaokaH Mori
Mar 3, 2004·Annals of Neurology·William E KlunkBengt Långström
Jan 31, 2006·Neuroimaging Clinics of North America·Susanne G MuellerLaurel Beckett
Apr 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Eric M ReimanRichard J Caselli
Feb 15, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Abhinay D JoshiUNKNOWN Florbetapir F 18 Study Investigators
Feb 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Chun-Fang XiaHartmuth C Kolb
Oct 9, 2013·Acta Neuropathologica·Clifford R JackVladimir Kepe
May 14, 2014·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Richard K J BrownKirk A Frey
Oct 22, 2014·Medical Image Computing and Computer-assisted Intervention : MICCAI·Holger R RothRonald M Summers
Dec 30, 2014·Brain : a Journal of Neurology·Niklas MattssonUNKNOWN Alzheimer's Disease Neuroimaging Initiative*
Apr 1, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Osama SabriUNKNOWN Florbetaben Phase 3 Study Group
May 20, 2015·JAMA : the Journal of the American Medical Association·Rik OssenkoppeleDavid J Brooks
May 29, 2015·Nature·Yann LeCunGeoffrey Hinton
Mar 13, 2016·Neurology·Susan M LandauUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 11, 2017·NeuroImage. Clinical·Hannelore K van der BurghMartijn P van den Heuvel
Jul 18, 2017·IEEE Journal of Biomedical and Health Informatics·Hongyang Jiang Yan Li
Apr 15, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackUNKNOWN Contributors
Sep 29, 2018·Alzheimer's Research & Therapy·Mara Ten KateFrederik Barkhof
Oct 16, 2018·Journal of Alzheimer's Disease : JAD·Si Eun KimSang Won Seo
Feb 15, 2019·Scientific Reports·Garam LeeUNKNOWN for Alzheimer’s Disease Neuroimaging Initiative
Aug 20, 2019·Alzheimer's Research & Therapy·Paula M PetroneUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Apr 22, 2020·European Journal of Nuclear Medicine and Molecular Imaging·Xikai TangJohan Nuyts
May 13, 2020·IEEE Transactions on Bio-medical Engineering·Coen de VenteMitko Veta
Jun 12, 2020·NeuroImage·Leonie HenschelMartin Reuter
Oct 4, 2020·BMC Neurology·Peter LeeUNKNOWN Alzheimer’s Disease Neuroimaging Initiative

❮ Previous
Next ❯

Software Mentioned

SPM12
MATLAB
PyTorch
CAM
SPSS

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

© 2021 Meta ULC. All rights reserved